Fosun Pharma’s COVID-19 Vaccine Starts Clinical Phase, Approved by Chinese NMPA
The giant Chinese pharmaceutical’s preventive vaccine is entering a new phase, bringing it closer to future commercialization.
Fosun Pharma’s COVID-19 preventive vaccine has been approved by the National Medical Products Administration to enter clinical trials. If the vaccine passes Phase III, it can officially go to the market into a commercial-stage. Considering the large-scale impact brought by the pandemic, there is a considerable consumption market for prevention.
The progress is the fruit of cooperative work. Exclusively authorized this March by BioNTech SE (BNTX:Nasdaq), Germany-based biotechnology, Fosun Pharma has been developing an mRNA-based vaccine for COVID-19 and owns the related commercial rights.
Selected reportsMore
Healthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
EqualOcean Analysis
Read next
In-depth
Healthcare
Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital
Updated 3 hours ago
In-depth
Technology
Successful Multinational Corporations in China Series: Qualcomm China
Jun 25, 2022 02:02 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.